UPCOMING TRAINING EVENTS

  1. ONCOLOGY AESTHETICS FOUNDATION TRAINING (OAFT) – LONDON

    July 9 @ 8:00 am - July 11 @ 5:00 pm
  2. ONCOLOGY AESTHETICS WORKSHOP (OAW) : TEL AVIV

    July 13 @ 9:00 am - 2:00 pm
Home>Articles and News>Melanoma Treatment With Vemurafenib Can Trigger Leukemia

Melanoma Treatment With Vemurafenib Can Trigger Leukemia

Vemurafenib, an RAF inhibitor being used for metastic melanoma needs to be carefully monitored in patients as it appears to trigger off leukemia.  Tough battle, trying to figure out what drugs work for which cancer.  It is recommended that adjuvant treatment with RAF only be offered in the context of a clinical trial.

One side effect from Vemurafenib are cutaneous skin conditions.  This has occurred in approximately 1/4 of all patients/clients while being administered with this drug.

(N.Engl.J.Med. 2012;367:1694-703 [doi:10.1056/NEJMoa1210093]).

 

By | 2012-11-13T09:14:39+00:00 November 13th, 2012|Articles and News|Comments Off on Melanoma Treatment With Vemurafenib Can Trigger Leukemia